X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA DIVIS LABORATORIES NATCO PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 10.6 31.7 33.4% View Chart
P/BV x 2.8 7.2 39.6% View Chart
Dividend Yield % 1.6 0.6 250.5%  

Financials

 NATCO PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
DIVIS LABORATORIES
Mar-18
NATCO PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,0801,142 94.6%   
Low Rs671533 125.9%   
Sales per share (Unadj.) Rs592.1146.6 403.9%  
Earnings per share (Unadj.) Rs188.433.0 570.3%  
Cash flow per share (Unadj.) Rs206.338.4 537.3%  
Dividends per share (Unadj.) Rs8.2510.00 82.5%  
Dividend yield (eoy) %0.91.2 78.9%  
Book value per share (Unadj.) Rs833.6222.8 374.1%  
Shares outstanding (eoy) m36.90265.47 13.9%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.55.7 25.9%   
Avg P/E ratio x4.625.3 18.3%  
P/CF ratio (eoy) x4.221.8 19.5%  
Price / Book Value ratio x1.13.8 28.0%  
Dividend payout %4.430.3 14.5%   
Avg Mkt Cap Rs m32,311222,318 14.5%   
No. of employees `0004.810.8 44.9%   
Total wages/salary Rs m3,2564,561 71.4%   
Avg. sales/employee Rs Th4,522.53,616.0 125.1%   
Avg. wages/employee Rs Th674.0423.8 159.0%   
Avg. net profit/employee Rs Th1,439.0814.9 176.6%   
INCOME DATA
Net Sales Rs m21,84838,915 56.1%  
Other income Rs m4041,134 35.6%   
Total revenues Rs m22,25240,049 55.6%   
Gross profit Rs m9,28412,617 73.6%  
Depreciation Rs m6621,425 46.5%   
Interest Rs m15413 1,157.9%   
Profit before tax Rs m8,87212,313 72.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,9203,543 54.2%   
Profit after tax Rs m6,9528,770 79.3%  
Gross profit margin %42.532.4 131.1%  
Effective tax rate %21.628.8 75.2%   
Net profit margin %31.822.5 141.2%  
BALANCE SHEET DATA
Current assets Rs m21,30745,351 47.0%   
Current liabilities Rs m5,9206,507 91.0%   
Net working cap to sales %70.499.8 70.6%  
Current ratio x3.67.0 51.6%  
Inventory Days Days73127 57.8%  
Debtors Days Days10795 111.9%  
Net fixed assets Rs m14,98621,160 70.8%   
Share capital Rs m369531 69.5%   
"Free" reserves Rs m30,35358,625 51.8%   
Net worth Rs m30,76059,156 52.0%   
Long term debt Rs m00-   
Total assets Rs m37,15167,832 54.8%  
Interest coverage x58.6926.8 6.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.60.6 102.5%   
Return on assets %19.112.9 147.7%  
Return on equity %22.614.8 152.4%  
Return on capital %29.320.8 140.8%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m10,32232,359 31.9%   
Fx outflow Rs m2,9789,042 32.9%   
Net fx Rs m7,34323,317 31.5%   
CASH FLOW
From Operations Rs m4,6367,759 59.8%  
From Investments Rs m-11,155-4,783 233.2%  
From Financial Activity Rs m6,509-3,142 -207.2%  
Net Cashflow Rs m-18-166 10.8%  

Share Holding

Indian Promoters % 52.0 52.0 100.1%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 11.8 66.4%  
FIIs % 16.6 19.0 87.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 17.2 151.2%  
Shareholders   25,395 31,796 79.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   MERCK  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 248 Points Higher; Power and Metal Stocks Witness Buying(Closing)

Indian share markets continued their momentum and ended their day on a strong note today. Gains were largely seen in the power sector, metal sector, and capital goods sector.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

INDIABULLS VENTURES Plunges by 5%; BSE 500 Index Up 0.9% (Market Updates)

May 27, 2019 | Updated on May 27, 2019

INDIABULLS VENTURES share price has plunged by 5% and its current market price is Rs 324. The BSE 500 is up by 0.9%. The top gainers in the BSE 500 Index are NARAYANA HRUDAYALAYA LTD (up 14.0%) and HONEYWELL AUTOMATION (up 9.1%). The top losers are INDIABULLS VENTURES (down 5.2%) and DIVIS LABORATORIES (down 9.7%).

DIVIS LABORATORIES Plunges by 10%; BSE HEALTHCARE Index Down 0.3% (Market Updates)

May 27, 2019 | Updated on May 27, 2019

DIVIS LABORATORIES share price has plunged by 10% and its current market price is Rs 1,730. The BSE HEALTHCARE is down by 0.3%. The top gainers in the BSE HEALTHCARE Index are NARAYANA HRUDAYALAYA LTD (up 13.3%) and FDC LTD. (up 5.5%). The top losers is DIVIS LABORATORIES (down 10.2%)..

DIVIS LABORATORIES Plunges by 5%; BSE HEALTHCARE Index Down 0.2% (Market Updates)

May 27, 2019 | Updated on May 27, 2019

DIVIS LABORATORIES share price has plunged by 5% and its current market price is Rs 1,730. The BSE HEALTHCARE is down by 0.2%. The top gainers in the BSE HEALTHCARE Index are NARAYANA HRUDAYALAYA LTD (up 9.8%) and FDC LTD. (up 8.1%). The top losers is DIVIS LABORATORIES (down 5.0%)..

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

My Top 7 Stocks to Buy as Modi Returns to Power(The 5 Minute Wrapup)

May 23, 2019

The Modi government is all set to come back to power. With a stable government at the centre, how should you play the stock market?

What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)

May 17, 2019

Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


May 27, 2019 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS